LMO1 and acute lymphoblastic leukemia: The favorable impact of TLX1 (92% 3y-OS, n = 44), LMO1 (89% 3y-OS, n = 8) and NKX2-1 (100% 3y-OS, n = 4) was not only found in the overall cohort but also within the already good risk subgroup of thymic T-ALL patients (Fig. 5E).